These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
298 related articles for article (PubMed ID: 10948447)
41. [Selective estrogen receptor modulators (SERMs) in the practice]. Nagykálnai T Magy Onkol; 2002; 46(2):165-75. PubMed ID: 12202896 [TBL] [Abstract][Full Text] [Related]
42. Rationale for using raloxifene to prevent both osteoporosis and breast cancer in postmenopausal women. Lee WL; Chao HT; Cheng MH; Wang PH Maturitas; 2008 Jun; 60(2):92-107. PubMed ID: 18534794 [TBL] [Abstract][Full Text] [Related]
48. Tamoxifen for prevention of breast cancer. Med Lett Drugs Ther; 1999 Jan; 41(1043):1-2. PubMed ID: 9924486 [No Abstract] [Full Text] [Related]
49. Prevention of hormone-related cancers: breast cancer. Dunn BK; Wickerham DL; Ford LG J Clin Oncol; 2005 Jan; 23(2):357-67. PubMed ID: 15637398 [TBL] [Abstract][Full Text] [Related]
50. [Chemoprevention of breast cancer. Impact of a new therapeutic strategy]. Kattan J; Ghosn M J Med Liban; 1999; 47(5):284-5. PubMed ID: 10887527 [No Abstract] [Full Text] [Related]
51. Tamoxifen, screening and new oestrogen receptor modulators. Neven P; Vergote I Best Pract Res Clin Obstet Gynaecol; 2001 Jun; 15(3):365-80. PubMed ID: 11476559 [TBL] [Abstract][Full Text] [Related]
52. Effect of raloxifene on the incidence of invasive breast cancer in postmenopausal women with osteoporosis categorized by breast cancer risk. Lippman ME; Cummings SR; Disch DP; Mershon JL; Dowsett SA; Cauley JA; Martino S Clin Cancer Res; 2006 Sep; 12(17):5242-7. PubMed ID: 16951244 [TBL] [Abstract][Full Text] [Related]
53. [Which is the better choice, estrogen or SERMs in postmenopausal women?]. Shintani M Clin Calcium; 2004 Oct; 14(10):105-10. PubMed ID: 15577140 [TBL] [Abstract][Full Text] [Related]
54. Tamoxifen for the prevention of breast cancer: yes. Vogel VG; Saenz M Important Adv Oncol; 1995; ():187-200. PubMed ID: 7672805 [No Abstract] [Full Text] [Related]
56. [Results of the NSABP clinical trial for the prevention of cancer of the breast]. Namer M Bull Cancer; 1998 Apr; 85(4):299. PubMed ID: 9752291 [No Abstract] [Full Text] [Related]
57. The gynecologic effects of lasofoxifene, an estrogen agonist/antagonist, in postmenopausal women. Archer DF Menopause; 2011 Jan; 18(1):6-7. PubMed ID: 21173718 [No Abstract] [Full Text] [Related]
58. [Current perspective of chemoprevention in breast cancer]. Asaga S; Jinno H; Sakata M; Kitajima M Nihon Rinsho; 2007 Jun; 65 Suppl 6():627-32. PubMed ID: 17682221 [No Abstract] [Full Text] [Related]
59. Tamoxifen for the prevention of breast cancer. Greenspan EM Am J Med; 1996 Jun; 100(6):665. PubMed ID: 8678089 [No Abstract] [Full Text] [Related]
60. Tipping the balance for the primary prevention of breast cancer. Vogel VG J Natl Cancer Inst; 2010 Nov; 102(22):1683-5. PubMed ID: 21051657 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]